These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 33908275

  • 1. The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia.
    Spargo A, Yost C, Squires P, Raju A, Schroader B, Brown JD.
    J Manag Care Spec Pharm; 2021 May; 27(5):554-564. PubMed ID: 33908275
    [Abstract] [Full Text] [Related]

  • 2. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
    Dusetzina SB, Huskamp HA, Winn AN, Basch E, Keating NL.
    JAMA Oncol; 2018 Jun 14; 4(6):e173598. PubMed ID: 29121177
    [Abstract] [Full Text] [Related]

  • 3. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers.
    Dusetzina SB, Huskamp HA, Jazowski SA, Winn AN, Wood WA, Olszewski A, Basch E, Keating NL.
    J Natl Cancer Inst; 2020 Oct 01; 112(10):1055-1062. PubMed ID: 31883008
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps.
    Dusetzina SB, Huskamp HA, Jazowski SA, Winn AN, Basch E, Keating NL.
    JAMA Health Forum; 2021 May 01; 2(5):e210673. PubMed ID: 35977314
    [Abstract] [Full Text] [Related]

  • 5. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL, Begley CE, Chan W, Krause TM.
    J Manag Care Spec Pharm; 2019 Oct 01; 25(10):1140-1150. PubMed ID: 31556823
    [Abstract] [Full Text] [Related]

  • 6. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL, Begley CE, Chan W, Krause TM.
    Am J Clin Oncol; 2020 Jul 01; 43(7):517-525. PubMed ID: 32304434
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.
    Vyas A, Descoteaux A, Kogut S, Parikh MA, Campbell PJ, Green A, Westrich K.
    J Manag Care Spec Pharm; 2022 Aug 01; 28(8):831-844. PubMed ID: 35876294
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia.
    Darkow T, Maclean R, Joyce GF, Goldman D, Lakdawalla DN.
    Am J Manag Care; 2012 Nov 01; 18(11 Suppl):S272-8. PubMed ID: 23327459
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
    Trivedi D, Landsman-Blumberg P, Darkow T, Smith D, McMorrow D, Mullins CD.
    J Manag Care Spec Pharm; 2014 Oct 01; 20(10):1006-15. PubMed ID: 25278323
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.